Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
192
394
|
| Price Target |
|
We'll email you a reminder when the closing price reaches IDR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Diagnos Laboratorium Utama PT Tbk
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | ID |
| Market Cap | 287.5B IDR |
| Net Margin |
-3%
|
| Country | US |
| Market Cap | 91.8B USD |
| Net Margin |
1%
|
| Country | US |
| Market Cap | 87.7B EUR |
| Net Margin |
1%
|
| Country | US |
| Market Cap | 73B USD |
| Net Margin |
1%
|
| Country | DE |
| Market Cap | 24.9B EUR |
| Net Margin |
3%
|
| Country | US |
| Market Cap | 20.1B USD |
| Net Margin |
3%
|
| Country | DE |
| Market Cap | 18.8B EUR |
| Net Margin |
-2%
|
| Country | US |
| Market Cap | 18.3B USD |
| Net Margin |
9%
|
| Country | US |
| Market Cap | 13.7B USD |
| Net Margin |
7%
|
| Country | DE |
| Market Cap | 12.4B EUR |
| Net Margin |
3%
|
| Country | AU |
| Market Cap | 13.4B AUD |
| Net Margin |
6%
|
Diagnos Laboratorium Utama PT Tbk
Glance View
PT Diagnos Laboratorium Utama Tbk engages in the provision of health support service. The company employs 54 full-time employees The company went IPO on 2021-01-15. The firm is engaged in providing health support services, such as health laboratories, other diagnostic drawing centers, blood testing laboratories, pharmaceutical warehouses, eye banks, sperm banks and blood banks, organ transplant banks, and other medical support services. The company operates through providing health services using laboratories segment. The Company’s products and services include clinical pathology laboratory, anatomy pathology laboratory, genomic laboratory, homecare health services, corporate health services, and Covid-19 checkup. The firm serves markets, such as Jakarta, Depok, Bali, Bandung, Bekasi, Padang, Makassar, Tangerang Selatan, Dumai, Batam, Purwakarta, Karawang, and Brebes. The company has branch offices in Ciputat (South Tangerang), Denpasar (Bali), Padang (West Sumatra), and Makassar, South Sulawesi.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Diagnos Laboratorium Utama PT Tbk's most recent financial statements, the company has Net Margin of -3.1%.
You don't have any saved screeners yet
